Compare PLG & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLG | INO |
|---|---|---|
| Founded | 2000 | 1979 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.7M | 167.5M |
| IPO Year | 2002 | 1999 |
| Metric | PLG | INO |
|---|---|---|
| Price | $0.86 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 1.1M | ★ 18.9M |
| Earning Date | 11-30-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | N/A | $434.61 |
| Revenue Next Year | N/A | $23,912.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $0.90 | $0.56 |
| 52 Week High | $4.04 | $2.72 |
| Indicator | PLG | INO |
|---|---|---|
| Relative Strength Index (RSI) | 28.65 | 63.16 |
| Support Level | N/A | $1.08 |
| Resistance Level | $1.44 | $1.94 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 4.61 | 63.18 |
Platinum Group Metals Ltd is a development-stage company, conducts work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa. Key metals of economic interest on the company's mineral properties include platinum, palladium, rhodium, gold, copper, and nickel. The company operates in one segment, the development of the Waterberg Project in South Africa, and geographically in Canada and South Africa.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.